Literature DB >> 7491787

The human immunodeficiency virus type 1 Vpu protein: a potential regulator of proteolysis and protein transport in the mammalian secretory pathway.

M J Vincent1, M Abdul Jabbar.   

Abstract

HIV-1 Vpu is a small transmembrane phosphoprotein of 16 kDa which performs critical roles in CD4 proteolysis and virus release. Previous studies have demonstrated that Vpu-induced degradation of CD4 occurs in the endoplasmic reticulum (ER), and that the proteolytic process is sequence specific requiring both the transmembrane and cytoplasmic domains of CD4. In the present study, we investigated the effects of Vpu expression on the intracellular membrane trafficking pathway of mammalian cells. In singly transfected cells, the HIV envelope glycoproteins and vesicular stomatitis virus glycoprotein (VSV G) were properly transported to the cell surface undergoing oligosaccharide modifications characteristic of their movement through the Golgi complex. In contrast, the cell surface delivery of glycoproteins was severely impeded in cells expressing Vpu. Biochemical analyses revealed that Vpu expression blocked the transfer of proteins from the ER-Golgi complex to the plasma membrane in a dose- and protein-dependent manner. Soluble gp120 exhibited extreme transport defects in the presence of Vpu, whereas transmembrane proteins (e.g., gp160, VSV) responded only moderately to wild-type Vpu. To gain insight into Vpu-mediated transport inhibition, we performed mutational analysis of the CK-2 phosphorylation sites (serines at 52 and 56) in the Vpu protein. CK-2 phosphorylation of Vpu has been shown to regulate the activity of the protein in reactions that involve the proteolysis of CD4 in the ER. We demonstrate here that the phosphorylation mutant is defective in both sequence-specific degradation of VRE-containing substrates and the transport inhibition of gp120 and VSV-G in the secretory pathway. Thus, these experiments have revealed that Vpu-mediated proteolysis and transport inhibition are mechanistically coupled requiring the same structural elements of the Vpu protein in both processes. We propose that the primary effect of Vpu expression is to impede the secretion process and then access glycoproteins bearing the VRE for Vpu-mediated proteolysis in the ER of mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7491787     DOI: 10.1006/viro.1995.0035

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens.

Authors:  David Lau; Wilson Kwan; John Guatelli
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

2.  CD4-Dependent Modulation of HIV-1 Entry by LY6E.

Authors:  Jingyou Yu; Chen Liang; Shan-Lu Liu
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

3.  Misdirection of membrane trafficking by HIV-1 Vpu and Nef: Keys to viral virulence and persistence.

Authors:  Andrey Tokarev; John Guatelli
Journal:  Cell Logist       Date:  2011-05

4.  Putative alpha-helical structures in the human immunodeficiency virus type 1 Vpu protein and CD4 are involved in binding and degradation of the CD4 molecule.

Authors:  E Tiganos; X J Yao; J Friborg; N Daniel; E A Cohen
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

5.  The vpu protein of human immunodeficiency virus type 1 plays a protective role against virus-induced apoptosis in primary CD4(+) T lymphocytes.

Authors:  Satoshi Komoto; Shoutaro Tsuji; Madiha S Ibrahim; Yong-Gang Li; Jiranan Warachit; Koki Taniguchi; Kazuyoshi Ikuta
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

6.  Human immunodeficiency virus (HIV) type 1 Vpu induces the expression of CD40 in endothelial cells and regulates HIV-induced adhesion of B-lymphoma cells.

Authors:  Winnie W Henderson; Rebecca Ruhl; Paul Lewis; Matthew Bentley; Jay A Nelson; Ashlee V Moses
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

7.  HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A.

Authors:  Sebastian Bolduan; Philipp Hubel; Tatjana Reif; Veronika Lodermeyer; Kristin Höhne; Joëlle V Fritz; Daniel Sauter; Frank Kirchhoff; Oliver T Fackler; Michael Schindler; Ulrich Schubert
Journal:  Virology       Date:  2013-03-22       Impact factor: 3.616

8.  The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.

Authors:  Nanette Van Damme; Daniel Goff; Chris Katsura; Rebecca L Jorgenson; Richard Mitchell; Marc C Johnson; Edward B Stephens; John Guatelli
Journal:  Cell Host Microbe       Date:  2008-03-13       Impact factor: 21.023

9.  Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.

Authors:  Mathieu Dubé; Bibhuti Bhusan Roy; Pierre Guiot-Guillain; Julie Binette; Johanne Mercier; Antoine Chiasson; Eric A Cohen
Journal:  PLoS Pathog       Date:  2010-04-08       Impact factor: 6.823

10.  Regulation of virus release by the macrophage-tropic human immunodeficiency virus type 1 AD8 isolate is redundant and can be controlled by either Vpu or Env.

Authors:  U Schubert; S Bour; R L Willey; K Strebel
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.